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Abstract. Lung cancer is the leading cause of cancer related
deaths. Common molecular drivers of lung cancer are mutations in receptor tyrosine kinases (RTKs) leading to activation
of the phosphatidylinositol 3-kinase (PI3K)/Akt pro-growth,
pro-survival signaling pathways. Myristoylated alanine rich
C-kinase substrate (MARCKS) is a protein that has the ability
to mitigate this signaling cascade by sequestering the target
of PI3K, phosphatidylinositol (4,5)-bisphosphate (PIP 2). As
such, MARCKS has been implicated as a tumor suppressor,
though there is some evidence that MARCKS may be tumor
promoting in certain cancer types. Since the MARCKS function depends on its phosphorylation status, which impacts its
subcellular location, MARCKS role in cancer may depend
highly on the signaling context. Currently, the importance of
MARCKS in lung cancer biology is limited. Thus, we investigated MARCKS in both clinical specimens and cell culture
models. Immunohistochemistry scoring of MARCKS protein
expression in a diverse lung tumor tissue array revealed that
the majority of squamous cell carcinomas stained positive for
MARCKS while other histologies, such as adenocarcinomas,
had lower levels. To study the importance of MARCKS in
lung cancer biology, we used inducible overexpression of
wild-type (WT) and non-phosphorylatable (NP)-MARCKS
in A549 lung cancer cells that had a low level of endogenous
MARCKS. We found that NP-MARCKS expression, but not
WT-MARCKS, enhanced the radiosensitivity of A549 cells in
part by inhibiting DNA repair as evidenced by prolonged radiation-induced DNA double strand breaks. We confirmed the
importance of MARCKS phosphorylation status by treating
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several lung cancer cell lines with a peptide mimetic of the
phosphorylation domain, the effector domain (ED), which
effectively attenuated cell growth as measured by cell index.
Thus, the MARCKS ED appears to be an important target for
lung cancer therapeutic development.
Introduction
Myristoylated alanine rich C-kinase substrate (MARCKS) has
been described as having contradicting roles in cancer biology.
Studies of MARCKS in colon cancer, melanoma, prostate
cancer, hepatocellular carcinoma as well as glioblastoma
multiforme (GBM) have indicated that MARCKS behaves as
a tumor suppressor (1-5). In contrast, studies in breast cancer
and choloangiocarcinoma have suggested that MARCKS
expression correlates with poor prognosis (6,7). Collectively,
this information highlights the importance of the cellular
environment in driving MARCKS signaling. The significance
of MARCKS signaling with respect to growth and response to
treatment of lung cancer is under investigation.
Common drivers of lung cancer include the fusion protein,
anaplastic lymphoma kinase (ALK), and mutations and
hyperactivation of receptor tyrosine kinases (RTKs) such as:
epidermal growth factor receptor (EGFR), c-MET (hepatocyte
growth factor receptor, HGFR), insulin growth factor receptor 1
(IGF-1R) and fibroblast growth factor receptor (FGFR) (8).
RTKs phosphorylate and activate phosphatidylinositol
3-kinase (PI3K) which then phosphorylates phosphatidylinositol (4,5)-bisphosphate (PIP2) producing phosphatidylinositol
(3,4,5)-triphosphate (PIP3) (9). PIP3 serves as an anchoring and
activation site for the pleckstrin homology (PH) domain of
the pro-growth, pro-survival kinase, Akt, among others (10).
Importantly, MARCKS contains an effector domain (ED)
capable of binding to the plasma membrane through an
electrostatic interaction with PIP2 molecules, thereby sequestering them (11,12) and preventing their conversion to PIP3.
This can effectively attenuate Akt activity. However, when
the MARCKS ED is bound by calcium-calmodulin or phosphorylated by serine kinases such as protein kinase C (PKC)
or Rho-associated coiled-coil kinase (ROCK), MARCKS
releases PIP2 at the plasma membrane and migrates into the
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cytoplasm due to electrostatic repulsion by the phosphate
groups (13,14), though this is reversible through phosphatase
action (15).
MARCKS is expressed in human lung tissue; however,
investigation of MARCKS involvement in lung cancer biology
is limited (16). Hanada et al (17) found that MARCKS
expression may provide a possible biomarker and prognostic
indicator for human squamous cell carcinoma of the lung.
MARCKS expression was increased in tumor tissue compared
to adjacent normal tissue, and high MARCKS expression
by immunohistochemistry (IHC) was associated with poor
prognosis. Additionally, Chen et al (18) described MARCKS
being expressed in higher levels in non-small cell lung cancer
(NSCLC) compared to normal tissue. Using a peptide mimetic
targeting the N-terminal region of MARCKS, they were able
to reduce migration in in vitro as well as in vivo models.
In the present study, we investigated MARCKS expression
in multiple lung tumor pathologies. Moreover, we examined
the importance of MARCKS and selected MARCKS mutants
in terms of lung cancer cell phenotype, particularly in response
to ionizing radiation. Our data suggest a critical dependence of
the phosphorylation status of the MARCKS effector domain
(ED) with respect to radiosensitization.
Materials and methods
Cell culture. Human lung cancer cell lines A549, H1299, H1792
and H1975 (American Type Culture Collection, Manassas,
VA, USA) were cultured in RPMI-1640 with 10% fetal bovine
serum (FBS), 1% penicillin-streptomycin (pen-strep) and 1%
GlutaMAX (Invitrogen/Life Technologies, Grand Island, NY,
USA). 293FT human embryonic kidney cells (Invitrogen/Life
Technologies) were cultured in Dulbecco's modified Eagle's
medium (DMEM) with 10% FBS and 1% pen-strep. All cells
were maintained at 37˚C in 5% CO2.
Immunohistochemical tissue array. A lung tumor tissue
microarray (TMA) (cat. #BC041114) was purchased from US
Biomax, Inc. (Rockville, MD, USA). The TMA was deparaffinized in xylene followed by 100, 95 and 70% graded
ethanol solutions and rehydrated in dH 2 O. Endogenous
peroxidase was blocked by a 5-min incubation with 3%
hydrogen peroxide solution in phosphate-buffered saline
(PBS). The TMA was then incubated with sodium citrate
buffer (Dako, Carpinteria, CA, USA) for 20 min for antigen
retrieval. Non-specific interactions were blocked in 20-min
incubation (room temperature) in 5% bovine serum albumin
(BSA), 100 mM Tris (pH 8.2 to 8.5) solution. MARCKS
was stained with an anti-MARCKS primary antibody
(EP1446Y, 1 h at room temperature; Abcam, Cambridge,
MA, USA) followed by an anti-rabbit alkaline phosphatase
(AP) conjugated secondary antibody (Invitrogen; 1 h at room
temperature). Following the manufacturer's protocols, Vector
red (Vector Laboratories, Inc., Burlingame, CA, USA) was
used to detect MARCKS. Cells were counterstained with 1%
methyl green solution. Lastly, the TMA was dehydrated using
70% ethanol, 50/50 ethanol/xylene, 100% xylene gradations
and coverslip mounted using PROTOCOL SecureMount
(cat. #23-022‑208; Thermo Fisher Scientific, Waltham, MA,
USA). Images were captured using a Zeiss Observer A1

microscope using an AxioCam MRc 5 camera. A board certified pathologist scored each tissue in a blinded fashion using
a scale of 0, 0.5, 1, 2 or 3 with 0 equaling no detection and
3 being the highest intensity. The highest ethical standards
were followed while collecting and handling patient tumors
and information. Informed consent was obtained from each
patient before tumor collection.
Generation of lentiviral MARCKS constructs and packaging plasmids. The ViraPower HiPerform T-REx Gateway
Expression System (cat. #A11141) and the pENTR221
entry vector (pENTR221-MARCKS) containing the wildtype (WT) MARCKS sequence were purchased from
Invitrogen. The WT-MARCKS sequence from pENTR221MARCKS was cloned into the pLenti6.3/TO/V5-DEST
destination vector using Clonase from the Gateway
expression system per the manufacturer's protocol to yield
pLenti6.3/TO/V5-MARCKS-WT. The non-phosphorylatable
(NP) MARCKS construct, in which the 4 serines of the ED
were changed to alanines, was synthesized by GenScript
(GenScript USA, Inc., Piscataway, NJ, USA) and cloned into
the pUC57 vector. The psPAX2 packaging plasmid (Addgene
plasmid 12260; Addgene, Cambridge MA, USA) and pCMVVSV-G envelope plasmid (Addgene plasmid 8454) were
obtained from Addgene.
Viral vector production. 293FT cells (1.5x106) were plated in
7 ml of DMEM supplemented with 10% FBS without antibiotics onto a poly-D-lysine (cat. #P7886; Sigma) coated 10-cm
dish. Lipofectamine 2000 (27 µl) (cat. #11668; Invitrogen)
was combined with 1.5 ml Opti-MEM media (cat. #11058;
Invitrogen) and incubated for 5 min at room temperature.
An additional aliquot of 1.5 ml Opti-MEM media had 4 µg
of psPAX2, PCMV-VSV-G, and appropriate lentiviral vector
plasmid added. The plasmid and lipofectamine media were
mixed together and incubated for 20 min at room temperature.
The Lipofectamine-plasmid mixture was added to the 293FT
cells and incubated overnight. The following morning, media
was replaced with fresh DMEM supplemented with 10% FBS
and 1% pen-strep. Lentiviral supernatant was collected at 24 h,
filtered through a 0.45-µm filter, aliquoted and stored at -80˚C.
The QuickTiter p24 ELISA (Cell Biolabs, Inc., San Diego, Ca,
USA) was used to quantify lentivirus aliquots (3).
Stable cell line selection. A549 cells (5x105) were plated in
6-well plates and allowed to adhere overnight. The following
morning, similar amounts of p24 quantified lentiviral particles
containing tetracycline-repressor (TetR) plasmid was used to
infect the cells. The cells were incubated with 500 µl of virus
for 2 h, at 37˚C, in 5% CO2 followed by 3-day incubation in
growth media. Following 3 passages with 200 µg/ml geneticin
(G418; Life Technologies), A549 TetR cells were re-plated on
6-well plates at 5x105 cells/well for MARCKS lentiviral infection. An identical procedure as described above was performed
for MARCKS virus infection, except selection was with 8 µg/
ml blasticidin (Life Technologies). The tetracycline homologue,
doxycycline (2 µg/ml) was used to induce expression.
MARCKS peptide design. MARCKS-ED TAT peptide was
designed by conjugating the cell permeable HIV Tat peptide
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(cat. #61214; Anaspec, Fremont, CA, USA) via disulfide linkage
to the 25 amino acid ED sequence (KKKKKRFSFKKSFK
LSGFSFKKNKK) (19). The control sequence was designed
using the Expasy random peptide generator (http://www.
expasy.org/randseq) using the average amino acid composition computed from Swiss-Prot (CEIEEHAWNTVEMFSSF
PGTQLYNDA) to control for size of the peptide. To eliminate
the positive charge effect, lysine and arginine residues were
changed to glutamates and then conjugated with the HIV Tat
peptide. The lyophilized peptides were re-suspended in sterile
ddH2O at a stock concentration of 5 mM to be used for the
experiments.
iCELLigence assay. The iCELLigence platform (ACEA
Biosciences, Inc., CA, USA) was used to monitor the cell
response to doxycycline and radiation, by measuring real-time
changes in cellular impedance (20,21). Cells were plated in
duplicate and allowed to attach under identical conditions,
either overnight or for 7 h, before doxycycline addition. In the
case of radiation, both sham and radiation therapy (RT) plates
were removed from the incubator after exposure for the same
duration. For studies with MARCKS-ED peptide, lung cancer
cells were plated for 6 h before the addition of MARCKS-ED
peptide mimetic or control peptide.
Immunoblotting. Immunoblotting was performed as previously
described (3). Briefly, cells were lysed using MPER lysis buffer
supplemented with protease (cat. #P8340; Sigma-Aldrich,
St. Louis, MO, USA) and phosphatase inhibitors (SigmaAldrich #P0044 and P5726). Samples were separated by
electrophoresis through either an 8 or 10% SDS-polyacrylamide
gel (SDS-PAGE) and transferred to a PVDF membrane
(Immobilon; EMD Millipore, Billerica, MA, USA). Blots were
blocked in 5% milk, 1% BSA and probed with the following
antibodies at the manufacturer's recommended concentrations: phospho-MARCKS (Abcam ab81295), MARCKS
(Abcam ab52616), phospho-Akt (S473) (cat. #D9E, #4060;
Cell Signaling Technology, Danvers, MA, USA), phospho-Akt
(T308) (Cell Signaling Technology C31E5E, #2965), Akt
(Cell Signaling Technology C67E7, #4691), actin (Santa Cruz
Biotechnology, sc-1616), and V-5 (Invitrogen, R96125).
Clonogenic assay. Cells were diluted and plated in defined
numbers to give six replicates per treatment condition. After
6 h, the media was changed (with or without doxycycline)
and incubated overnight. The following morning, cells were
treated with 0, 3, 5 or 8 Gy of irradiation using a 320 kV X-ray
irradiator (Kimtron, Inc., Woodbury, CT, USA). After one
week, cells were fixed and stained with 6.0% glutaraldehyde
and 0.5% crystal violet. Colonies consisting of 50 or more
cells were counted for each condition. A surviving fraction
(S.F.) was calculated by using the equation (number of colonies formed/number of cells plated)/(number of colonies for
sham irradiated group/number of cells plated). The result was
plotted as the mean and the standard error of the mean in a
semi-logarithmic format (22,23). The dose enhancement ratio
(DER) was calculated as the dose (Gy) for the non-induced
A549 cells (doxycycline absent) divided by the dose for
induced A549 cells (doxycycline supplemented) for which a
survival fraction of 0.2 was achieved.
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Senescence associated β -galactosidase staining. β -gala
ctosidase was used as a marker for senescence using the Cell
Signal kit (cat. #9860). Cells were plated, attached overnight,
and then treated overnight with or without doxycycline. Cells
were exposed to 5 Gy and stained 1 week following irradiation. The manufacturer's protocol was followed and images
were captured on a Zeiss Observer A1 microscope using an
AxioCam MRc 5 camera. Five representative images per
condition were captured.
Mitotic catastrophe assay. Lung cancer cells were plated,
attached overnight, and then treated overnight with or without
doxycycline. Cells were exposed to 5 Gy of irradiation and
fixed with 4% paraformaldehyde 0, 24, 48, 72 and 96 h
following irradiation. Fixed cells were stained with 300 ng/ml
DAPI for 10 min and washed 3 times with PBS. Nine representative images per condition were captured using a Zeiss
Observer A1 microscope using an AxioCam MRc 5 camera.
Double-strand DNA damage quantification. Lung cancer
cells were plated onto sterile coverslips, attached overnight,
and then treated overnight with or without doxycycline. The
following day cells were treated with 8 Gy of irradiation. At the
indicated time-points, cells were rinsed in PBS and incubated
for 5 min, at 4˚C, in ice-cold buffer (10 mM Hepes/KOH,
pH 7.4, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl 2)
supplemented with 1% protease (Sigma #P8340) and 1%
phosphatase inhibitors (Sigma P0044 and P5726) followed by
fixation in 70% ethanol for 15 min. The cells were blocked and
incubated with primary antibodies (1:500 dilution, phosphoγH2AX Ser139, Millipore, cat. #MI-07-164). The secondary
antibody was the anti-rabbit Alexa Fluor 594-conjugated antibody (1:2,000 dilution; Invitrogen). DAPI was used for nuclear
staining. The coverslips were subsequently mounted onto
slides with mounting media (Aqua-Poly/Mount, cat. #18606;
Polysciences, Inc., Warrington, PA, USA) and analyzed via an
EVOS fl digital inverted fluorescence microscope (AMG; Life
Technologies). Positive and negative controls were included on
all experiments. A total of 500 cells were assessed. For foci
quantification, cells with >10 foci were counted as positive
according to the standard procedure (24-26).
Statistics. Statistical calculations and data graphing were
performed using the GraphPad Prism (GraphPad Software,
Inc., La Jolla, CA, USA). ANOVA was used for assessing
results in the clonogenic assay, senescence associated
β-galactosidase staining assay, mitotic catastrophe assay and
double-strand DNA damage quantification. All statistical tests
were two-sided and were performed using a significance level
of 5%.
Results
Lung tumor TMA staining for MARCKS expression. Previous
reports of MARCKS in lung cancer looked at the broad group
of NSCLC or squamous cell carcinomas but did not perform
a comprehensive analysis (17,18). We purchased a lung tumor
TMA from US Biomax, Inc. containing a total of 200 lung
tissue samples comprised of 62 adenocarcinoma, 12 atypical
carcinoid, 4 adenosquamous carcinoma, 8 bronchoalveolar
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Table I. Patient and immunohistochemical characteristics for selective lung cancer tissue staining for anti-MARCKS.
Characteristics
Average age, years
Gender, n (%)
Male
Female

Data
54
138 (69.7)
62 (31.3)

		
Histology
Positives per group (%)
Adenocarcinoma
Atypical carcinoid
Adenosquamous
Bronchoalveolar
Large cell
Mucinous adenocarcinoma
Papillary adenocarcinoma
Normal lung
Small cell
Squamous

Intensity
-------------------------------------------------------------------------------------------------------------3
2
1
0.5
n (%)
n (%)
n (%)
n (%)

17/62 (27.4)
2/12 (16.7)
1/4 (25.0)
1/8 (12.5)
0/8 (0.0)
1/2 (50.0)
0/4 (0.0)
6/20 (30.0)
2/16 (12.5)
35/64 (54.7)

0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
6 (9.5)

1 (1.6)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
2 (10.0)
0 (0)
4 (6.3)

3 (4.8)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
1 (5.0)
1 (6.3)
8 (12.7)

13 (21.3)
2 (16.7)
1 (25.0)
1 (12.5)
0 (0)
1 (50.0)
0 (0)
3 (15.0)
1 (6.3)
17 (26.6)

Grade
1
2
3
4

8/19 (42.1)
32/85 (37.6)
12/23 (52.2)
0 (0)

0 (0)
6 (7.1)
0 (0)
0 (0)

0 (0)
4 (4.7)
1 (4.3)
0 (0)

2 (10.5)
6 (7.1)
3 (13.0)
0 (0)

6 (31.6)
16 (18.8)
8 (34.8)
0 (0)

Stage
I
II
III
IV	

26/74 (35.1)
9/38 (23.7)
23/62 (37.1)
1/4 (25.0)

4 (5.4)
0 (0)
2 (3.2)
0 (0)

3 (4.1)
1 (2.6)
1 (1.6)
0 (0)

4 (5.4)
0 (0)
8 (12.9)
0 (0)

15 (20.3)
8 (21.1)
12 (19.4)
1 (25.0)

T
1
2
3
4

6/24 (25.0)
32/98 (32.7)
17/48 (35.4)
4/8 (50.0)

0 (0)
6 (6.1)
0 (0)
0 (0)

3 (12.5)
1 (1.0)
0 (0)
1 (12.5)

0 (0)
4 (4.1)
6 (14.6)
1 (12.5)

3 (12.5)
21 (21.4)
10 (20.8)
2 (25.0)

N
0
1
2

30/92 (32.6)
23/68 (33.8)
6/20 (30.0)

4 (4.3)
0 (0)
2 (10.0)

3 (3.3)
2 (2.9)
0 (0)

6 (6.5)
5 (7.4)
1 (5.0)

17 (18.5)
16 (23.5)
3 (15.0)

M
0
1

58/176 (33.0)
1/4 (25.0)

6 (3.4)
0 (0)

5 (2.8)
0 (0)

12 (6.8)
0 (0)

35 (19.9)
1 (25.0)

Staining intensity was scored on a scale of 0-3 with a score of 3 having the strongest staining for MARCKS. Images were captured at x100 on
a Zeiss Observer A1 microscope using an AxioCam MRc 5 camera.

carcinoma, 8 large cell carcinoma, 2 mucinous adenocarcinoma, 20 normal lung, 4 papillary adenocarcinoma, 16 small
cell carcinoma, and 64 squamous cell carcinoma tissue samples
using Biomax nomenclature (Table i). The TMA was stained
for MARCKS and scored in a blinded fashion using a 0-3 scale

as indicated in Fig. 1A. MARCKS could be detected in most
of the lung cancer histologies represented, but was positive
in a minority of the samples overall (Table i). Squamous cell
carcinoma had the highest percentage of samples stain for
MARCKS and there was a wide range of staining intensities.
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Figure 1. MARCKS protein expression and genetic alterations in human lung cancer. (A) A Biomax Inc. lung tumor tissue microarray was stained for
MARCKS and representative tissue images and scoring (indicated below each image) are shown for squamous cell carcinoma (top panel), adenocarcinoma
(middle panel), and normal lung tissue (lower panel). (B) Kaplan-Meier survival curve of The Cancer Genome Atlas lung adenocarcinoma dataset comparing
survival of patients with MARCKS gene alterations vs. patients without alterations (www.cBioPortal.com). The Kaplan-Meier method was used to obtain
estimates of survival, and survival curves were compared using the log-rank test (p-value shown).

For the squamous cell carcinoma samples: 6 tumors had the
highest intensity scoring of 3, 4 had an intensity score of 2,
8 scored an intensity of 1, and 17 cases scored a 0.5. In total,
35 out of 64 (54.7%) squamous cell carcinoma cases stained
positive for MARCKS expression. In contrast, adenocar-

cinomas had lower staining percentage and lower staining
intensity compared to squamous cell carcinoma. Overall, 17
out of 62 (27.4%) adenocarcinoma samples stained positive for
MARCKS though most of them were of 0.5 score (Table i and
Fig. 1A). The remaining tumor histologies had a much lower
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Figure 2. MARCKS and MARCKS mutant overexpression in lung cancer cell lines. (A) A549, H1299, H1792 and H1975 lung cancer cell lines were probed
by western blot analysis for phospho-MARCKS, MARCKS, Ser473-Akt, Thr308-Akt, Akt and actin. (B) A schematic diagram depicts the mutant MARCKS
constructs. MARCKS contains an N-terminal myristoylation domain, an MH2 domain and an effector domain (ED). The wild-type (WT)-MARCKS and nonphosphorylatable (NP)-MARCKS constructs as designed also contained a C-terminal V5 tag for differentiation from endogenous protein. The NP-MARCKS
four serine residues in the ED region were mutated to alanines (indicated in red). (C) Western blot analysis of stably selected A549 cells with control lentiviral
(CT), WT or NP MARCKS doxycycline-inducible expression. Cells were cultured with (+) or without (-) doxycycline for 18 h before western blotting.
MARCKS, phospho-MARCKS, V5 and actin antibodies were used. (D) V5 tagged wild-type MARCKS (WT MARCKS) or non-phosphorylatable MARCKS
(NP MARCKS) stably infected (by lentivirus) A549 cells were treated without (upper panel) or with (lower panel) 2 µg/ml doxycycline to induce expression.
Shown are confocal immunofluorescent images of anti-V5 (green) and DAPI nuclear staining (blue) as merged images.

rate of MARCKS staining. Notably, in normal lung tissue 2
samples had a staining intensity of 2, 1 sample had a staining
intensity of 1, and 3 samples had a staining intensity of 0.5. In
total, 6 out of 20 (30.0%) normal lung samples stained positive for MARCKS (Table i and Fig. 1A). cBioPortal (www.
cbioportal.org) (27,28) analysis of The Cancer Genome Atlas
(TCGA) dataset for lung adenocarcinomas showed that alterations in the MARCKS gene were associated with a significant
(p=0.046) decrease in survival (Fig. 1B).
MARCKS manipulation in lung cancer cells. In order to study
the importance of MARCKS in lung cancer, we analyzed
several lung cancer cell lines for MARCKS protein expression. Western blotting was performed and revealed that A549
and H1299 human lung cancer cell lines expressed low levels
of MARCKS. Alternatively, the human lung cancer cell lines
H1792 and H1975 expressed higher levels of MARCKS
(Fig. 2A). Therefore, we selected A549 for overexpression of
wild-type (WT) and non-phosphorylatable (NP) MARCKS
(shown schematically in Fig. 2B). Lentiviral particles were used
to establish WT-MARCKS and NP-MARCKS overexpression
in A549 cells under the regulation of a tetracycline-inducible
promoter as shown by western blotting (Fig. 2C). Because

MARCKS phosphorylation has been associated with its cytoplasmic localization (29), the NP-MARCKS construct (shown
schematically in Fig. 2B) should remain membrane bound
and more effectively sequester PIP2 than the WT-MARCKS.
As such, we used confocal immunofluorescence (Fig. 2D) to
determine the subcellular localization of WT-MARCKS vs.
NP-MARCKS by probing for the V5 epitope. Indeed confocal
imaging shows that WT-MARCKS was expressed predominately in the cytoplasm while the NP-MARCKS construct was
predominately localized to the plasma membrane region of the
cell.
NP-MARCKS decreases survival after radiation. The iCELLigence real-time impedance assay system (ACEA) was
used to screen for cell physiological differences between
WT-MARCKS and NP-MARCKS (Fig. 3A), particularly
after irradiation as MARCKS knockdown has been shown to
promote radiation resistance in GBM (3). Both WT-MARCKS
and NP-MARCKS samples were plated and had very similar
cell index (impedance) measurements for the first 6 h.
After 6 h, all WT-MARCKS and NP-MARCKS cells were
dosed with or without doxycycline overnight. The following
morning sham or 5 Gy of irradiation was administered to the
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Figure 3. NP-MARCKS overexpression alters the cellular function of A549 cells. (A) The Cell index of doxycycline-induced A549 WT-MARCKS was
measured with sham or 5 Gy of irradiation similarly to induced A549 NP-MARCKS under identical conditions. Time of doxycycline induction and radiation are indicated on the graph by the arrows. Cell index mean and standard deviation are shown. (B) A clonogenic assay of A549 WT-MARCKS cells with
(+) or without (-) doxycycline-induced overexpression. DER, dose enhancement ratio for a surviving fraction of 0.2. Data are expressed as means ± SEM.
(C) A549 NP-MARCKS with (+) and without (-) doxycycline induction were treated and colonies counted using a clonogenic assay (p<0.01). DER, dose
enhancement ratio.

cells. After two days of monitoring, we observed that both
the WT-MARCKS and NP-MARCKS irradiated groups had
lower Cell index measurements compared to their sham counterparts (Fig. 3A). In particular, the NP-MARCKS irradiated
cells had the lowest Cell index measurements overall. To
confirm these findings, A549 WT-MARCKS were cultured in
standard culture media without doxycycline (WT- or NP-) or
standard culture media with 2 µg/ml of doxycycline (WT+ or
NP+) for 18 h prior to performance of a clonogenic assay, the
gold standard assay for determining radiation sensitivity (30).
Two-way ANOVA testing calculated no significant difference between the WT-MARCKS (-) and WT-MARCKS
(+) groups (Fig. 3B). We postulated the lack of radiation
enhancement could be due to lack of membrane binding
(needed for PIP2 sequestration) of WT-MARCKS. In contrast
to WT-MARCKS, we observed a significant decrease in
survival with NP-MARCKS overexpression (p=0.01; two-way
ANOVA) (Fig. 3C). Overexpression of NP-MARCKS had a
radiation sensitizing effect on the A549 cells with a DER of
1.649. This experiment was repeated five times and similar
trends were observed.
Impaired DNA damage repair with NP-MARCKS overexpression. Previously, we have observed that overexpression
of wild-type MARCKS in GBM cells led to a state of cellular

senescence (3). To rule out senescence being the cause of
lower clonogenicity seen with NP-MARCKS expression, we
measured β -galactosidase, an enzyme upregulated during
senescence. Comparing WT-MARCKS with (+) and without
(-) doxycycline along with NP-MARCKS with (+) and
without (-) doxycycline there was no significant differences in
β-galactosidase positive cells 8 days post the 5 Gy irradiation
(Fig. 4A). In addition, we examined for mitotic catastrophe
following radiation exposure of these cells. Again, comparing
WT-MARCKS with (+) and without (-) doxycycline along
with NP-MARCKS with (+) and without (-) doxycycline
there was no significant mitotic catastrophe difference over
the course of 96 h post the 5 Gy irradiation (Fig. 4B). As we
observed no difference in senescence or mitotic catastrophe,
we anticipated that NP-MARCKS was influencing DNA
damage compared to WT-MARCKS. As shown in Fig. 4C,
DNA damage was studied by probing for DNA double-strand
breaks (DSB) by measuring γH2AX foci (26). As expected,
irradiation of A549 cells increased γH2AX foci formation
within 1-h post irradiation. At 24 h, all groups approached
basal level γH2AX foci formation except for NP-MARCKS
(+) overexpressing cells that demonstrated persistent γH2AX
foci staining, suggesting that NP-MARCKS promotes
prolonged DNA damage, leading to a decrease in cell survival
following radiation exposure.
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Figure 4. NP-MARCKS impact on DNA Double-strand breaks. (A) A549
WT-MARCKS with (+) or without (-) doxycycline and A549 NP-MARCKS
with (+) or without (-) doxycycline, β -galactosidase positive cells were
counted 8 days after 5 Gy. (B) A549 WT-MARCKS with (+) or without (-)
doxycycline and A549 NP-MARCKS with (+) or without (-) doxycycline cells
were counted for positive mitotic catastrophe events at the designated times
after 5 Gy. (C) γH2AX foci staining with >10 foci per cell were calculated
for A549 WT-MARCKS and A549 NP-MARCKS with (+) and without (-)
doxycycline at the designated times post the 8-Gy irradiation. **p<0.01;
***
p<0.001. Data are expressed as means ± SEM.

Figure 5. A MARCKS ED peptide mimetic impairs the lung cancer Cell index. Lung cancer cell lines (A) A549; (B) H1299; (C) H1792; (D) H1975 were plated
6 h before the addition of 25 µM of control peptide (red) or MARCKS ED peptide (green). Arrow indicates the time at which peptides were added to the culture.
Cell index mean and standard deviation are shown.

Using a MARCKS ED-targeting peptide mimetic in lung
cancer cells. Because MARCKS has no enzymatic activity, we
utilized a peptide mimetic to modulate MARCKS behavior by

targeting the ED of MARCKS. We engineered a cell permeable peptide mimetic composed of the cell permeable TAT
peptide conjugated to the 25 amino acid sequence (KKKKKR

INTERNATIONAL JOURNAL OF ONCOLOGY 46: 1079-1088, 2015

FSFKKSFKLSGFSFKKNKK) of the ED region of MARCKS
(19). A control peptide was generated based on the Expasy
random peptide generator using the average amino acid
composition computed from Swiss-Prot (CEIEEHAWNTV
EMFSSFPGTQLYNDA). This sequence was also conjugated
to TAT. A549, H1299, H1792 and H1975 lung cancer cell lines
were plated in the iCELLigence instrument for a proliferation
experiment with the MARCKS-ED or control peptide. In all
four cell lines, the control peptide group had an increased Cell
index over the duration of the assay (Fig. 5). However, the
MARCKS-ED TAT peptide treated cells showed a marked
decrease in their Cell index, suggesting that targeting the
MARCKS ED is a potential strategy against lung cancer.
Discussion
The role of MARCKS in the development and progression
of cancer is quite controversial in that there is evidence for
both tumor suppression (1-5) and tumor promotion (6,7).
As we have previously postulated (3), the cellular environment and co-existent signaling pathways almost certainly
contribute to the importance and role of MARCKS. In the
present study, we identified a key role of the ED of MARCKS
in terms of cellular response, particularly to radiation. The
ED of MARCKS is a very important domain as it determines MARCKS subcellular localization, binds PIP 2 and
F-actin allowing MARCKS to influence both proliferation
and migration of cancer cells. Intrinsic modulators of the
ED of MARCKS include serine kinases, including PKCs
and ROCKs, as well as calcium-calmodulin (Ca 2+ -CAM),
which bind in a mutually exclusive manner. Indeed, when
we induced expression of a non-phosphorylatable MARCKS
(that should not bind Ca 2+ -CAM either), we noted radiation sensitization concomitant with a prolongation of DNA
double strand breaks. Treatment with a peptide mimetic of
the ED was effective in blocking tumor cell growth as well.
These findings complement our previous work in GBM cell
lines (3) showing that loss of MARCKS promotes radiation
protection and increased cell growth, while overexpression
of MARCKS suppressed growth.
Recent studies of MARCKS in lung cancer have also
suggested that interfering with the N-terminal region of
MARCKS can manipulate cellular behavior. An N-terminal
peptide mimetic corresponding to the first 24 amino acids of
MARCKS reduced levels of phospho-MARCKS and inhibited
cellular migration (18). A proposed mechanism for a peptide
mimetic interfering with MARCKS function is that the peptide
therapy overwhelms the cell and prevents MARCKS from
cycling to and from the plasma membrane. This proposed
mechanism is consistent with the decreased levels of phosphoMARCKS observed in our studies. Several studies have shown
that phosphorylated MARCKS (cytoplasmic localization)
promotes cancer cell migration (7,31). The role of MARCKS
expression and subcellular localization upon cell migration is
reported to be influenced by the cycling of MARCKS from
the plasma membrane to the cytoplasm and back to the plasma
membrane (32), which is consistent with our observations.
Additionally, MARCKS contains two actin binding sites in the
ED, that are disrupted by ED phosphorylation, thus preventing
cross-linking (33). MARCKS may have additional indirect

1087

effects on this process since actin-binding proteins, such as
Arp2/3 and N-WASP, bind to PIP 2, once again, pointing to
the importance of the ability of MARCKS to sequester the
phospholipid (34).
Additionally, we describe here the expression pattern
of the MARCKS protein in a variety of human lung tumor
histologies. To the best of our knowledge, the present study
is the first to report such findings. MARCKS expression was
predominately expressed in the adenocarcinoma and squamous cell carcinoma tumor samples. Other cases, including
small cell carcinoma and atypical carcinoid had very few
samples that stained positive for MARCKS. Currently, we
cannot comment on clinical outcomes relative to MARCKS
protein expression since the TMA lacked outcome data.
However, as discussed above, the cellular response to
MARCKS expression will depend on its phosphorylation status and cellular localization, which has not been
consistently examined in clinical specimens. For example
Hanada et al (17) described that squamous cell carcinomas
with higher MARCKS expression had poorer prognosis, yet,
neither phosphorylation status or subcellular location was
described. Future work on MARCKS, particularly in lung
cancer, will require a more in depth investigation beyond
gene expression or protein expression levels to include the
status of MARCKS modulators and ED phosphorylation.
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